Fairbanks Capital Management Inc. purchased a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the third quarter, according to its most recent disclosure with the SEC. The firm purchased 44,643 shares of the biopharmaceutical company’s stock, valued at approximately $3,617,000. Gilead Sciences makes up 3.5% of Fairbanks Capital Management Inc.’s investment portfolio, making the stock its 7th largest position.
Several other hedge funds also recently modified their holdings of GILD. Cubist Systematic Strategies LLC grew its holdings in shares of Gilead Sciences by 118.6% during the 3rd quarter. Cubist Systematic Strategies LLC now owns 22,966 shares of the biopharmaceutical company’s stock worth $1,861,000 after purchasing an additional 12,460 shares in the last quarter. Kalos Management Inc. acquired a new stake in Gilead Sciences in the 3rd quarter valued at $278,000. Cedar Hill Associates LLC acquired a new stake in Gilead Sciences in the 3rd quarter valued at $269,000. Beacon Investment Advisory Services Inc. boosted its stake in Gilead Sciences by 271.1% in the 3rd quarter. Beacon Investment Advisory Services Inc. now owns 63,660 shares of the biopharmaceutical company’s stock valued at $5,158,000 after buying an additional 46,504 shares in the last quarter. Finally, Violich Capital Management Inc. boosted its stake in Gilead Sciences by 1.9% in the 3rd quarter. Violich Capital Management Inc. now owns 86,931 shares of the biopharmaceutical company’s stock valued at $7,043,000 after buying an additional 1,649 shares in the last quarter. 76.47% of the stock is currently owned by institutional investors and hedge funds.
Shares of Gilead Sciences, Inc. (NASDAQ GILD) traded down $0.25 on Thursday, hitting $81.57. The stock had a trading volume of 3,997,174 shares, compared to its average volume of 10,040,000. Gilead Sciences, Inc. has a one year low of $63.76 and a one year high of $89.54. The company has a market cap of $106,890.00, a PE ratio of 23.44, a price-to-earnings-growth ratio of -1.85 and a beta of 1.22. The company has a quick ratio of 3.48, a current ratio of 3.55 and a debt-to-equity ratio of 1.10.
The business also recently announced a quarterly dividend, which will be paid on Thursday, March 29th. Investors of record on Friday, March 16th will be given a dividend of $0.57 per share. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.52. This represents a $2.28 annualized dividend and a yield of 2.80%. The ex-dividend date is Thursday, March 15th. Gilead Sciences’s dividend payout ratio (DPR) is currently 59.77%.
GILD has been the subject of several research analyst reports. ValuEngine upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research report on Thursday, February 8th. Credit Suisse Group set a $80.00 target price on Gilead Sciences and gave the stock a “hold” rating in a research report on Wednesday, January 3rd. Leerink Swann dropped their target price on Gilead Sciences from $86.00 to $83.00 and set a “market perform” rating for the company in a research report on Wednesday, February 7th. Mizuho lifted their price objective on Gilead Sciences from $77.00 to $83.00 and gave the stock a “buy” rating in a research note on Wednesday, November 8th. Finally, BMO Capital Markets decreased their price objective on Gilead Sciences from $89.00 to $83.00 and set an “outperform” rating for the company in a research note on Friday, October 27th. One research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $87.04.
In other news, insider John C. Martin sold 73,333 shares of Gilead Sciences stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $74.98, for a total value of $5,498,508.34. Following the completion of the transaction, the insider now directly owns 3,070,099 shares of the company’s stock, valued at approximately $230,196,023.02. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Gregg H. Alton sold 15,000 shares of Gilead Sciences stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $73.87, for a total value of $1,108,050.00. Following the completion of the transaction, the executive vice president now directly owns 64,613 shares of the company’s stock, valued at $4,772,962.31. The disclosure for this sale can be found here. Over the last three months, insiders sold 418,333 shares of company stock valued at $32,742,108. Corporate insiders own 1.30% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Fairbanks Capital Management Inc. Takes $3.62 Million Position in Gilead Sciences, Inc. (NASDAQ:GILD)” was originally posted by Week Herald and is the sole property of of Week Herald. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://weekherald.com/2018/02/15/fairbanks-capital-management-inc-takes-3-62-million-position-in-gilead-sciences-inc-gild.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.